Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
- PMID: 26366173
- PMCID: PMC4558455
- DOI: 10.1155/2015/651757
Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
Abstract
The glucagon-like peptide-1 is secreted by intestinal L cells in response to nutrient ingestion. It regulates the secretion and sensitivity of insulin while suppressing glucagon secretion and decreasing postprandial glucose levels. It also improves beta-cell proliferation and prevents beta-cell apoptosis induced by cytotoxic agents. Additionally, glucagon-like peptide-1 delays gastric emptying and suppresses appetite. The impaired secretion of glucagon-like peptide-1 has negative influence on diabetes, hyperlipidemia, and insulin resistance related diseases. Thus, glucagon-like peptide-1-based therapies (glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) are now well accepted in the management of type 2 diabetes. The levels of glucagon-like peptide-1 are influenced by multiple factors including a variety of nutrients. The component of a meal acts as potent stimulants of glucagon-like peptide-1 secretion. The levels of its secretion change with the intake of different nutrients. Some drugs also have influence on GLP-1 secretion. Bariatric surgery may improve metabolism through the action on GLP-1 levels. In recent years, there has been a great interest in developing effective methods to regulate glucagon-like peptide-1 secretion. This review summarizes the literature on glucagon-like peptide-1 and related factors affecting its levels.
Figures
Similar articles
-
Is glucagon-like peptide 1 an incretin hormone?Diabetologia. 1999 Mar;42(3):373-9. doi: 10.1007/s001250051165. Diabetologia. 1999. PMID: 10096792 Review.
-
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.Metabolism. 2014 Jan;63(1):9-19. doi: 10.1016/j.metabol.2013.09.010. Epub 2013 Oct 17. Metabolism. 2014. PMID: 24140094 Review.
-
Biologic actions and therapeutic potential of the proglucagon-derived peptides.Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):22-31. doi: 10.1038/ncpendmet0017. Nat Clin Pract Endocrinol Metab. 2005. PMID: 16929363 Review.
-
Nutrients related to GLP1 secretory responses.Nutrition. 2013 Jun;29(6):813-20. doi: 10.1016/j.nut.2012.11.015. Epub 2013 Feb 12. Nutrition. 2013. PMID: 23415393 Review.
-
Biological actions and therapeutic potential of the glucagon-like peptides.Gastroenterology. 2002 Feb;122(2):531-44. doi: 10.1053/gast.2002.31068. Gastroenterology. 2002. PMID: 11832466 Review.
Cited by
-
Recent advances in understanding the role of glucagon-like peptide 1.F1000Res. 2020 Apr 6;9:F1000 Faculty Rev-239. doi: 10.12688/f1000research.20602.1. eCollection 2020. F1000Res. 2020. PMID: 32269764 Free PMC article. Review.
-
Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women.Nutrients. 2021 Mar 6;13(3):865. doi: 10.3390/nu13030865. Nutrients. 2021. PMID: 33800785 Free PMC article.
-
Amino Acid-Induced Impairment of Insulin Signaling and Involvement of G-Protein Coupling Receptor.Nutrients. 2021 Jun 29;13(7):2229. doi: 10.3390/nu13072229. Nutrients. 2021. PMID: 34209599 Free PMC article. Review.
-
The Association Between Femoral Artery Intima-Media Thickness and Serum Glucagon-Like Peptide-1 Levels Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus.Diabetes Metab Syndr Obes. 2020 Oct 7;13:3561-3570. doi: 10.2147/DMSO.S264876. eCollection 2020. Diabetes Metab Syndr Obes. 2020. PMID: 33116707 Free PMC article.
-
Effect of hypoxia on GLP-1 secretion - an in vitro study using enteroendocrine STC-1 -cells as a model.Pflugers Arch. 2024 Oct;476(10):1613-1621. doi: 10.1007/s00424-024-02996-z. Epub 2024 Jul 29. Pflugers Arch. 2024. PMID: 39075239 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources